Press Room


Diabetic retinopathy Market worth more than $11bn by 2023

Diabetic Retinopathy Market size will exceed USD 11 billion by 2023; as reported in the latest study by Global Market Insights, Inc.
 

Increasing incidence and prevalence of diabetes, rapid growth in incidence of blindness associated with diabetes, due to complication associated with diabetic retinopathy, increase in number of geriatric population globally, and enhanced awareness for early diagnosis of diabetic retinopathy will be key factors for strengthening the demand global diabetic retinopathy market
 

Non-proliferative diabetic retinopathy (NPDR) being the initial stage of diabetic retinopathy accounts for maximum market share over the forecast period. While, proliferative diabetic retinopathy PDR is caused when the NPDR goes untreated and PDR may cause more extreme vision loss than NPDR because it can affect peripheral and central vision.
 

Request Sample Buy NowInquiry Before Buying

 

Non-proliferative diabetic retinopathy accounted for over 70% of the global market in 2015. Being earlier stage of diabetic retinopathy patients avoid further complications and try and get cured before their vision is permanently damaged. LATAM is set account for over 10% of the global market share in throughout the forecast period. Disposable income and other demographic trends, as well as strong awareness level, make Brazil attractive in terms of availability large patient pool and supply chain accessible from U.S.
 

Anti-VEGF accounted for over 90% of market share during the forecast period and will lose its market share collectively to intraocular steroid injection, laser surgery, and vitrectomy.
 

Browse key industry insights spread across 73 pages with 32 market data tables & 8 figures & charts from the report, “Diabetic retinopathy Market Size by Type (Proliferative Diabetic retinopathy, Non-Proliferative Diabetic retinopathy), By Management (Anti VEGF Drug, Intra-ocular Steroid Injections, Laser Surgeries, Vitrectomy), Industry Analysis Report, Regional Outlook (U.S, Canada, UK, Germany, China, Japan, Brazil, South Africa,), Growth Potential, Price Trends, Competitive Market Share & Forecast, 2016 – 2023” in detail along with the table of contents:
https://www.gminsights.com/industry-analysis/diabetic-retinopathy-market-report
 

Germany Anti-VEGF market size was over USD 500 million in 2015. Optimistic indicators from medical industry for curing cataracts, macular degeneration, and preventing heart diseases fueled demand. Healthcare industry expansion along with raise in consumer affordability have positively affect the regional growth.
 

Asia Pacific diabetic retinopathy market share will witness significant gains increasing at 5% CAGR. Favorable clinical guidelines and government initiatives are expected to increase the diagnosis and treatment rate, thereby fueling the growth.
 

Lack of skilled ophthalmologists coupled with increasing incidences of diabetes mellitus are the crucial growth drivers for of diabetic retinopathy market in Brazil. MEA diabetic retinopathy market has witnessed notable growth. South Africa dominates the industry, increase in the geriatric population will propel the market for diabetic retinopathy.
 

In terms of terrestrial presence major companies include, Actavis, Alimera Sciences, Ampio Pharmaceuticals, Bayer Healthcare, BCN Peptides, Genentech, Glycadia Pharmaceuticals, Kowa Group, Novartis AG, Regeneron Pharmaceuticals, Sirnaomics Incorporation and ThromboGenics.
 

Diabetic retinopathy market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2012 to 2023, for the following segments:

Diabetic Retinopathy Market By Type

  • Proliferative Diabetic Retinopathy
  • Non-proliferative diabetic retinopathy

Diabetic retinopathy market by management

  • Anti-VEGF
  • Intraocular Steroid Injection
  • Laser Surgery
  • Vitrectomy

The above information is provided on a regional and country basis for the following:

  • North America
    • U.S.
    • Canada
  • EU
    • UK
    • Germany
  • Asia Pacific
    • China
    • Japan
  • Latin America (LATAM)
    • Brazil
  • Middle East
    • South Africa